The persistence of IL-17A+ cells within the airway mucosa of people with chronic lung disease may not only sustain inflammation, but may also alter essential host defence to respiratory infections, leading to excessive inflammatory responses during exacerbations. Here, IL17A is linked to respiratory tract infectious disorder.